KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Work In Process (2023 - 2025)

Aurinia Pharmaceuticals' Work In Process history spans 3 years, with the latest figure at $44.7 million for Q4 2025.

  • For Q4 2025, Work In Process rose 21.93% year-over-year to $44.7 million; the TTM value through Dec 2025 reached $44.7 million, up 21.93%, while the annual FY2025 figure was $44.7 million, 21.93% up from the prior year.
  • Work In Process reached $44.7 million in Q4 2025 per AUPH's latest filing, up from $42.6 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $44.7 million in Q4 2025 to a low of $36.6 million in Q4 2024.
  • Average Work In Process over 3 years is $41.0 million, with a median of $42.2 million recorded in 2025.
  • Peak YoY movement for Work In Process: decreased 2.01% in 2024, then grew 21.93% in 2025.
  • A 3-year view of Work In Process shows it stood at $37.4 million in 2023, then fell by 2.01% to $36.6 million in 2024, then grew by 21.93% to $44.7 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Work In Process are $44.7 million (Q4 2025), $42.6 million (Q3 2025), and $43.2 million (Q2 2025).